Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study.
Deborah Meyran, Arnaud Petit, Joelle Guilhot...
https://pubmed.ncbi.nlm.nih.gov/32799036/Actively Recruiting
Led by Poitiers University Hospital · Updated on 2024-01-17
750
Participants Needed
20
Research Sites
N/A
Total Duration
Researchers are studying chronic myeloid leukemia CML, a rare blood cancer, in children and adolescents under 18 years old. This international observational study aims to better understand the characteristics, treatment approaches, and prognostic factors of pediatric CML. It also seeks to evaluate the long-term effects of treatments, especially tyrosine kinase inhibitors, on growth and development in this young population. The study collects both retrospective and prospective data from medical records and databases, without administering new treatments or interventions. Data gathered include demographic details, diagnosis information, treatment histories, and follow-up outcomes. National coordinating centers in participating countries gather anonymized patient data and send it to a central data center in France for analysis. Participants data are collected and updated twice yearly, with ongoing monitoring to describe patient characteristics and treatment policies. Researchers analyze survival, response to treatment, side effects, and long-term outcomes. The study is expected to continue for about five years, with results shared regularly with participating centers and published anonymously.
CONDITIONS
International Chronic Myeloid Leukemia Pediatric Study
F
Frederic MILLOT, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Poitiers University Hospital
Lead Sponsor
CIC Inserm 1402
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants with Chronic Myeloid Leukemia are observed through collection of retrospective and prospective medical and demographic data, including follow-up assessments twice a year.
Biannual visits for data collection
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Deborah Meyran, Arnaud Petit, Joelle Guilhot...
https://pubmed.ncbi.nlm.nih.gov/32799036/Frédéric Millot, Natacha Maledon, Joelle Guilhot...
https://pubmed.ncbi.nlm.nih.gov/31082688/Frédéric Millot, Joëlle Guilhot, Meinolf Suttorp...
https://pubmed.ncbi.nlm.nih.gov/28838993/Poitiers University Hospital
Lead Sponsor
CIC Inserm 1402
Collaborating Sponsor